| Date | Title | Description |
| 19.12.2025 | FoRx Therapeutics Secures €42M for Next-Gen PARG Inhibitor Cancer Therapy | FoRx Therapeutics secured €42 million ($50 million) in Series A funding. The Swiss biotech targets advanced cancers. Its lead candidate, FORX-428, is a novel PARG inhibitor. This drug disrupts the DNA Damage Response. It aims to treat tumor... |
| 18.12.2025 | FoRx Therapeutics raises $50 million to advance clinical trials |
Existing investors, including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures participated in the financing including a first closing in June 2024, which provided funding through the Investigational New Drug (IND) ... |
| 01.12.2025 | Protego Biopharma: $130 Million Series B Funding Closed To Advance Pivotal AL Amyloidosis Program | Protego Biopharma has closed an oversubscribed $130 million Series B financing round that will accelerate its first-in-class AL amyloidosis therapeutic program into a pivotal clinical study. The round was led by Novartis Venture Fund and Fo... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing.
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 08.09.2025 | NRG Therapeutics Secures £50M to Advance Neurodegenerative Disease Therapies | NRG Therapeutics just closed a monumental £50 million Series B financing. This oversubscribed round fuels vital neurodegenerative disease research. The UK-based firm targets mitochondrial dysfunction. Its lead program, NRG5051, aims to trea... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND | Stevenage, UK, 8 September 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B f... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND |
Stevenage, UK, 8 September 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B ... |
| 11.06.2025 | EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio | EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio
Wed, Jun 11, 2025 09:30 CET Report this content
Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as... |
| 28.05.2025 | FORE Biotherapeutics: A New Dawn in Cancer Treatment with $38 Million Series D-2 Financing | In the ever-evolving landscape of cancer treatment, a new player is making waves. FORE Biotherapeutics, based in Philadelphia, has secured $38 million in Series D-2 financing. This funding marks a significant step forward in the company's m... |
| 23.05.2025 | FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of Plixorafenib | FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare... |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con... |
| 25.04.2025 | Granite Bio debuts with $100 million to tackle autoimmune diseases |
Granite Bio is a biotechnology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions. Its pipeline comprises two lead candidates. GRT-001 depletes pro-infl... |
| 15.01.2025 | RhyGaze raises CHF 86 million to advance gene therapy for retinal diseases |
RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, who is a scientific co-founder of R... |
| 13.01.2025 | RhyGaze Closes USD 86M Series A Funding | RhyGaze, a Basel, Switzerland- and Philadelphia, PA-based biotechnology company developing gene therapies for retinal diseases, raised USD 86M in Series A funding.
The round was led by GV (Google Ventures), alongside Arch Venture Partners, ... |
| 13.01.2025 | RhyGaze: $86 Million (Series A) Raised To Develop Gene Therapies For Retinal Diseases | RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, announced that it has raised a Series A funding round of $86 million. The funding round was led by GV (Google Ventures), alongside Arch Venture Partners, F-... |
| 28.07.2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
| 27.07.2024 | CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series D | CatalYm announced the completion of a $150 million Series D financing. The oversubscribed funding round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde... |
| 16.10.2023 | AstronauTx, developing treatments for Alzheimer's, raises $59M Series A | The startup works in partnership with UCL and is backed by Novartis and UK gov't funds
In the United States alone, about 10.7% of people age 65 and older are living with Alzheimer's – the most common form of dementia. That number is project... |
| 09.10.2023 | AstronauTx closes a £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease | London UK, XXXX– AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders today announced the completion of a £48 million ($61 million) Series A financing.... |
| 04.07.2023 | Venture Leaders Biotech 2023: Captain’s Blog by Navignostics, Mosanna Therapeutics, Limula, and Tandem Therapeutics | Venture Leaders Biotech 2023: Captain’s Blog by Navignostics, Mosanna Therapeutics, Limula, and Tandem Therapeutics 04.07.2023 12:46, Rita Longobardi linkedIn facebook twitter instagram youtube -->
In mid-June, the Venture Leaders Biotec... |
| 26.06.2023 | Dutch-based Tagworks Pharmaceuticals raises €59.5M to design effective, safe systemic therapies | The Netherlands-based Tagworks Pharmaceuticals, a company that claims to be a pioneer of Click-to-Release chemistry to deliver effective and safer systemic therapies, announced on Thursday, June 22, that it has raised $65M (approximately €5... |
| 03.03.2023 | Oculis goes public on Nasdaq | |
| 18.10.2022 | Oculis to go public via SPAC | |
| 02.03.2022 | London-based Epsilogen nabs £30.75 million to develop antibodies for cancer treatment | London-based startup that develops novel immunoglobulin antibodies to treat cancer, Epsilogen has raised £30.75 million ($41.20 million) in oversubscribed funding. The Series B round was led by Novartis Venture Fund and joined by 3B Future ... |
| 16.12.2021 | Anaveon raises CHF 110 million | |
| 07.05.2021 | Oculis closes US$57 million Series C financing | The oversubscribed round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Cap... |
| 07.05.2021 | Oculis closes US$57 million Series C financing | |
| 13.09.2019 | Anokion raises $40 million and acquires US biotech startup | |
| 05.06.2019 | The UZH Life Sciences Fund investS CHF1M in an anti-obesity drug | |
| 27.02.2019 | UZH spinoff secures CHF 35 million Series A financing | |
| 11.06.2018 | In the heart of one of the biggest Life Sciences hubs - tales from a Swiss entrepreneur in Boston | In the heart of one of the biggest Life Sciences hubs - tales from a Swiss entrepreneur in Boston 11.06.2018 09:00, Charlotte Pichon linkedIn facebook twitter instagram youtube -->
Venture Leaders Life Sciences team member Mathieu Horras... |
| 20.02.2018 | Nine Dairy Farm Tech Startups Seeking to Bolster a Troubled Industry | Whether it be single-cow farms in India or massive commercial dairies in the US, the dairy industry is under pressure in light of changing market forces and consumer preferences.
In 2014, India’s dairy industry grew to be larger than that o... |
| 05.01.2018 | Oculis raises CHF20 million and moves to Switzerland | |
| 04.01.2018 | Oculis Raises $20.3M Series B from Novartis Venture Fund | Oculis (www.oculis.com), a clinical-stage biotechnology company focused on the development of breakthrough non-invasive topical treatment for back-of-the-eye diseases, announced it has successfully closed a Series B financing round of CHF 2... |
| 21.11.2017 | Women in Agtech: Joy Parr Drach of Advanced Animal Diagnostics is Done with Double Standards | Joy Parr Drach is CEO of Advanced Animal Diagnostics (AAD), a company developing tools to diagnose livestock disease on the farm. The Research Triangle Park, North Carolina-based company aims to help cut back on the number of antibiotics ad... |
| 07.10.2015 | Daily funding roundup - October 7, 2015 | AppDirect raised $140M; CampoRico Fertilizers secured $40M; OptiNose nabbed $30M
TNI medical AG, a Würzburg, Germany-based medical device company, raised €3 million ($3.36 million) in venture capital funding. Pathena Fund made the investmen... |
| 24.07.2015 | Daily funding roundup - July 24, 2015 | Northleaf Venture Catalyst Fund closed $300M; Voxel8 received $12M; AdAgility raised $1.6M
AdAgility, a provider of personalized, on-site and mobile, cross-selling solutions, raised $1.6 million to further accelerate its already impressive ... |
| - | London-based Epsilogen nabs £30.75 million to develop antibodies for cancer treatment | London-based startup that develops novel immunoglobulin antibodies to treat cancer, Epsilogen has raised £30.75 million ($41.20 million) in oversubscribed funding. The Series B round was led by Novartis Venture Fund and joined by 3B Future ... |
